ISPPD-12 International Symposium on Pneumococci and Pneumococcal Diseases

The ISPPD-12 International Symposium on Pneumococci and Pneumococcal Diseases covers topics such as:

• Pneumococcal Ecology
  • Serotype replacement: evidence, impact, regional variations
  • ​Carriage / colonisation
  • Microbiome
  • Vaccine-driven serotype and genotype changes
  • Biofilms
  • Clinical implications of microbiota findings
  • The relationships between carriage / disease and between carriage / transmission
  • Nasopharyngeal microbial ecology
  • Pneumococcal and viral interactions
  • Viruses and influence of nasal microbiome on colonisation and infection
  • Phase variation​
  • Antibiotic resistance: biology and molecular mechanisms
• Burden of Pneumococcal Disease​
  • Impact of PCV in developing countries
  • ​​​Global epidemiology post-PCV
  • Pre-PCV introduction surveillance
  • Paediatric disease post-PCV
  • HIV and pneumococcus
  • Improving outcome in sepsis and meningitis
  • Co-infections and pneumococcus
  • Non-pulmonary disease: pleura, meningitis, cardiac involvement etc
  • Pathophysiology of pneumococcal disease
  • Antimicrobial resistance: epidemiology and regional variation
  • Non-vaccine interventions for prevention of pneumococcal disease​
  • How should we target vulnerable groups with effective vaccination strategies?
• ​Bacterial Genomics
  • Genome-wide pneumococcal analyses
  • Vaccine driven serotype/genotype changes
  • How genomic data contribute to disease protection/spread etc
  • Genomic epidemiology
  • Epigenetics
  • Comparative genomics
  • Functional genomics
  • Pneumococcal biology and evolution
  • GWAS
  • Antimicrobial resistance
  • New sequencing technologies
  • RNAseq / transcriptomics
  • ​
  • Databases / data analyses​
• ​Ongoing Challenge of Pneumonia
  • Improving outcome in clinical pneumonia
  • Impact of PCV on pneumonia
  • Pneumonia in children
  • Pneumonia endpoints
  • Management of disease
  • Diagnostics
  • PERCH
  • Treatment of disease
  • Environmental contributory factors (smoking, pollution, nutrition)​
• The Unique Challenge of Pneumococcal Disease in Adults
  • Vaccine use in adults
  • Pneumococcal disease in adults
  • Diagnostics
  • NCD`s and the pneumococcus: implications of changes in NCD epidemiology eg. the rise of diabetes and obesity
  • Meningitis
  • Pneumonia in adults​
  • ​
  • HIV​
• Mechanisms Underlying Host Susceptibility to Disease
  • Genetic susceptibility to colonisation
  • Genetic susceptibility to disease
  • Host pathogen interactions
  • Disparities in susceptibility to pneumococcal disease
  • Specific immune responses to vaccines and disease
  • Other contributing factors like smoke, viruses and nutrition
  • ​
  • Investigation for primary immunodeficiency ​
• New Pneumococcal Vaccines​​
  • Alternative vaccines to PCV10/13 including proteins, new PCVs
  • Alternative vaccine strategies / adjuvants / immunomodulation
  • Vaccine aimed to reduce transmission rather than protect recipients directly
  • Novel vaccine targets and immune mechanisms
  • Practicalities and ethics of getting new vaccines and antigens to the clinic
  • Licensing / how to do a trial with a new vaccine
  • Vaccine safety

The ISPPD-12 International Symposium on Pneumococci and Pneumococcal Diseases brings together clinicians, scientists, public health, industry and policy experts, academics and students from Asia and around the world.

The next ISPPD-12 International Symposium on Pneumococci and Pneumococcal Diseases will be held in Toronto, Canada on 19-23 Jun 2021.